Diagnosis, Pancreas Cancer
Conditions
Keywords
Pancreatic cancer, hypoxanthine/xanthine concentration in urine
Brief summary
* This study aim to develope a diagnostic method of pancreatic cancer by using a reagent for analyzing purine metabolite (Hypoxanthine, Xanthine) in urine. * It is safe and cost effective compare to radiologic or blood test. It can be used for initial screening test for healty population.
Detailed description
* CubeBio and Seoul National University Bundang Hospital signed a joint technology development agreement to compare the analytical performance of existing analytical methods and purine metabolite analysis reagents developed by CubeBio. * Through quantitative analysis of hypoxanthine and xanthine in the urine of normal people and pancreatic cancer patients, we plan to confirm the possibility of diagnosing pancreatic cancer using reagents for analyzing purine metabolites. * Early diagnosis of pancreatic cancer is a key determinant of cure and survival rates, and impact on all aspects of cancer, including rate of progression, treatment, and prognosis. * This study could change the paradigm of pancreatic cancer screening by evaluating the stability and accuracy of urinary purine metabolite analysis reagents.
Interventions
DEVICEPurine metabolite (Hypoxanthine, Xanthine) in urine by CubeBio
* Collect urine from the patient to measure urinary hypoxia, xanthine concentration. * Hypoxic acid, xanthine analysis in urine using High Performance Liquid Chromatography (HPLC). * After that, hypoxanthine and xanthine will be analyzed using purine metabolite analysis reagents. * Compare the cutoff of the metabolic value of Pancreas cancer clarified in the existing research and the value of the sample.
Sponsors
Seoul National University Bundang Hospital
Ho-Seong Han
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
1. pancreatic cancer group Inclusion Criteria: * Pancreatic ductal adenocarcinoma that is pathologically confirmed or shows characteristic radiologic features * Patients with resectable pancreatic cancer at the time of surgery (Including borderline resectable pancreatic cancer at the time of diagnosis or Locally advanced pancreatic cancer after chemotherapy or radiation therapy) * Patients without invasion of adjacent organs other than the left adrenal gland and mesocolon * Patients with informed consent
Exclusion criteria
* History of other malignancy (Inclusive if there is no evidence of recurrence after 5 years of treatment) * Patient with Inflammatory disease(e.g. severe pancreatitis, cholangitis) * Patients with underlying diseases at high risk of general anesthesia * Other subject whom the investigator deems inappropriate 2. control group Inclusion Criteria included healthy individuals as well as patients with benign diseases.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Urine | 1 day | mean concentration of purine metabolites in urine |
Countries
South Korea
Contacts
Primary ContactMeeYoung Kang, M.D.
Outcome results
None listed